The company and all members of the Board of Directors guarantee that the content of the information disclosure is true, accurate, and complete, without false records, misleading statements, or major omissions.
I. Meeting Details
The first meeting of the Twelfth Board of Directors of Lizhu Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") was held on May 29, 2026, through on-site and remote voting. All directors unanimously agreed to waive the notice period for the meeting. A total of 10 directors were supposed to attend, and all 10 directors were present. The meeting was chaired by Mr. Tang Yanggang, who was jointly nominated by more than half of the directors, and senior management attended the meeting. The meeting complied with relevant laws, administrative regulations, departmental rules, normative documents, and the Company’s Articles of Association.
II. Resolutions Passed
After careful deliberation by the attending directors, the following resolutions were made:
(1) Election of the Chairman and Vice Chairman
The proposal regarding the election of the Company’s Chairman and Vice Chairman was approved. In accordance with the Company’s Articles of Association and considering the needs of corporate governance and development, Mr. Zhu Baoguo was elected as the Chairman of the Twelfth Board of Directors, and Mr. Tang Yanggang was elected as the Vice Chairman, both serving a three-year term from the date of this Board meeting's approval until the expiration of the Twelfth Board's term. Specific details can be found in the announcement disclosed on the same day in the "China Securities Journal," "Securities Times," "Securities Daily," "Shanghai Securities Journal," and on the website of Giant Tide Information (www.cninfo.com.cn).
Voting results: 10 votes in favor, 0 votes against, 0 abstentions.
(2) Election of Specialized Committee Members
The proposal regarding the election of members of the Twelfth Board of Directors' specialized committees was approved. The specific committee members are as follows: